Patients with mHSPC benefited from darolutamide + ADT + docetaxel irrespective of age (<75 years and ≥75 years), with consistent improvements in overall survival, time to mCRPC, and time to initiation ...

His wife convinced him to go for a "man check" which eventually led to a prostate cancer diagnosis, a move from New Zealand to Australia and a place in a world-first medical trial. Subscribe for FREE ...

A ground-breaking treatment for cancer described by doctors as being like a ‘heat seeking missile’ has boosted survival rates and quality of life for patients with fewer side effects.

The Elekta Unity MR-LINAC system, used at Allegheny General Hospital, combines MRI imaging with radiation therapy to target cancerous cells with pinpoint precision.

Nubeqa plus ADT improved rPFS in mHSPC regardless of disease volume, reducing the risk of radiological progression or death ...

Real-world data highlight gaps in genetic testing and targeted therapy use for metastatic castration-resistant prostate ...

Patients with mCRPC taking LuPSMA had a median OS of 34 months vs 26 months with enzalutamide alone.

GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Fred Saad discussing a subgroup analysis of the phase 3 ARANOTE trial assessing darolutamide + ADT in patients with ...

With a new treatment for prostate cancer in play, men with more aggressive forms of prostate cancer may have a more positive ...

With delays in biomarker testing and treatment for metastatic castration-resistant prostate cancer, continued education is ...

Cancer researcher Karen Sfanos says she is 'terrified' of the impact of cuts to NIH funding that supports vital biomedical ...